Survival benefits of fibrinolysis and early aspirin in acute myocardial infarction are sustained
Fibrinolytic therapy for patients with acute myocardial infarction has
short term survival benefits, but information about long term effects
is limited. Baigent et al (p 1337) report long term survival data from
the ISIS-2 trial of intravenous streptokinase and one month's oral
aspirin in suspected acute myocardial infarction. They found that
the early survival benefits of fibrinolytic therapy persist for at
least 10 years and do not seem to increase or decrease with prolonged
follow up in any category of patients, including elderly patients. The
survival benefits of aspirin also persist and are additional to those
of fibrinolytic therapy.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
Relevant Article
- ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither
- Colin Baigent, Rory Collins, Paul Appleby, Sarah Parish, Peter Sleight, and Richard Peto
BMJ 1998 316: 1337-1343.[Abstract] [Full Text] [PDF]
This Article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Find similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Related Content
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article. Print issues
